Burkholderia pseudomallei is the etiologic agent of melioidosis. This disease is endemic to tropical and subtropical regions of the world but is now considered an emerging disease, as well as a disease of biodefense importance. Because of B. pseudomallei's intrinsic resistance to many antibiotics, melioidosis therapy is difficult and, because of the tendency of the bacterium to become latent, must be continued for extended periods of time. The limited spectrum of antibiotics available for melioidosis treatment, and theemergence of resistant strains in endemic regions calls for development of new therapeutics. Furthermore, successful treatment of infections caused by bioterrorism events involving strains which have acquired additional resistance determinants, whether by natural means or by malicious genetic engineering, may be impossible without new therapeutics. We hypothesize that several new investigational drugs, some of which are in clinical trials, may also be efficacious against B. pseudomallei.
Two specific aims will be pursued to test this hypothesis.
In Aim 1, in vitro efficacies of BAL30072 (a monobactam), cethromycin (a ketolide) and iclaprim (a trimethoprim analog) will be assessed against a panel of >100 clinical and environmental isolates, establishing MIC90 values in the process and time-kill curves for each antibiotic for asubset of these isolates. Chromosomally encoded p-lactamase genes will be expressed and evaluated as potential BAL30072 resistance mechanisms.
In aim 2, then, in vivo therapeutic efficacy of BAL30072, cethromycin and iclaprim will be assessed in a BALB/c mouse model of acute B. pseudomallei infection using proven melioidosis therapeutics as controls. As these investigational drugs are in Phase I throughPhase III clinical trials for other indications, demonstration of in vitro and in vivo activity against B. pseudomallei will enable rapid advancement of these antimicrobials to experiments with non-human primates and into Phase I clinical trials.Public Health relevance. Closely related bacteria also cause difficult or impossible to cure infections and we believe that it is likely that the advances we made with B. pseudomallei therapeutics will be directly applicable to infections by other biothreat agents such as B. mallei and perhaps the emerging pathogen B. Cenocepacia

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54AI065357-04
Application #
7688234
Study Section
Special Emphasis Panel (ZAI1-KLW-M (M1))
Project Start
2008-05-01
Project End
2009-04-30
Budget Start
2008-05-01
Budget End
2009-04-30
Support Year
4
Fiscal Year
2008
Total Cost
$156,794
Indirect Cost
Name
Colorado State University-Fort Collins
Department
Type
DUNS #
785979618
City
Fort Collins
State
CO
Country
United States
Zip Code
80523
Webb, Jessica R; Price, Erin P; Somprasong, Nawarat et al. (2018) Development and validation of a triplex quantitative real-time PCR assay to detect efflux pump-mediated antibiotic resistance in Burkholderia pseudomallei. Future Microbiol 13:1403-1418
York, Joanne; Nunberg, Jack H (2018) A Cell-Cell Fusion Assay to Assess Arenavirus Envelope Glycoprotein Membrane-Fusion Activity. Methods Mol Biol 1604:157-167
Rhodes, Katherine A; Somprasong, Nawarat; Podnecky, Nicole L et al. (2018) Molecular determinants of Burkholderia pseudomallei BpeEF-OprC efflux pump expression. Microbiology 164:1156-1167
Randall, Linnell B; Georgi, Enrico; Genzel, Gelimer H et al. (2017) Finafloxacin overcomes Burkholderia pseudomallei efflux-mediated fluoroquinolone resistance. J Antimicrob Chemother 72:1258-1260
Podnecky, Nicole L; Rhodes, Katherine A; Mima, Takehiko et al. (2017) Mechanisms of Resistance to Folate Pathway Inhibitors in Burkholderia pseudomallei: Deviation from the Norm. MBio 8:
Cummings, Jason E; Slayden, Richard A (2017) Transient In Vivo Resistance Mechanisms of Burkholderia pseudomallei to Ceftazidime and Molecular Markers for Monitoring Treatment Response. PLoS Negl Trop Dis 11:e0005209
Pettey, W B P; Carter, M E; Toth, D J A et al. (2017) Constructing Ebola transmission chains from West Africa and estimating model parameters using internet sources. Epidemiol Infect 145:1993-2002
Furuta, Yousuke; Komeno, Takashi; Nakamura, Takaaki (2017) Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci 93:449-463
Skyberg, Jerod A; Lacey, Carolyn A (2017) Hematopoietic MyD88 and IL-18 are essential for IFN-?-dependent restriction of type A Francisella tularensis infection. J Leukoc Biol 102:1441-1450
Plumley, Brooke A; Martin, Kevin H; Borlee, Grace I et al. (2017) Thermoregulation of Biofilm Formation in Burkholderia pseudomallei Is Disrupted by Mutation of a Putative Diguanylate Cyclase. J Bacteriol 199:

Showing the most recent 10 out of 258 publications